GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Achiko AG (XSWX:ACHI) » Definitions » DeferredTaxAndRevenue

Achiko AG (XSWX:ACHI) DeferredTaxAndRevenue : CHF0.00 Mil (As of Jun. 2022)


View and export this data going back to 2019. Start your Free Trial

What is Achiko AG DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Achiko AG's current deferred tax and revenue for the quarter that ended in Jun. 2022 was CHF0.00 Mil.

Achiko AG DeferredTaxAndRevenue Historical Data

The historical data trend for Achiko AG's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achiko AG DeferredTaxAndRevenue Chart

Achiko AG Annual Data
Trend Dec18 Dec19 Dec20 Dec21
DeferredTaxAndRevenue
- - - -

Achiko AG Semi-Annual Data
Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22
DeferredTaxAndRevenue Get a 7-Day Free Trial - - - - -

Achiko AG DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Achiko AG's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Achiko AG (XSWX:ACHI) Business Description

Traded in Other Exchanges
N/A
Address
Tessinerplatz 7, Zurich, CHE, CH-8002
Achiko AG is developing disruptive diagnostic solutions that put people first. The company product is a rapid, reliable Covid-19 test with a companion app offering a user-friendly digital health passport. Achiko creates and develops aptamer-based diagnostics through its biotechnology division, AptameX, and companion health apps via its digital mobile health technology division, Teman Sehat. The AptameX DNA aptamer tests can be rapidly chemically synthesized, are cost-effective, and have wide potential across multiple disease diagnostics. Leveraging AptameX and Teman Sehat, Achiko aims to deliver fast, accurate, and affordable diagnostic testing for a range of pathogenic diseases and therapeutic indications in the rapidly evolving healthcare diagnostics field.

Achiko AG (XSWX:ACHI) Headlines

No Headlines